cdr

Hot Keywords
Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Original Articles See more
Review Articles See more
Others See more
Most Cited Papers In Last Two Years See more
Ongoing Special Issues See more
Special Issue Ebooks See more
About The Journal
  • ISSN

    2578-532X (Online)

    Publisher

    OAE Publishing Inc.

    Article Processing Charge

    OAE Publishing Inc. undertakes Article Processing Charge for authors

  • Editor-in-Chief

    Godefridus J. Peters

    Publishing Model

    Gold Open Access

    Copyright

    Copyright is retained by authors

  • Publishing Frequency

    Quarterly published

    Contact Us

    editorial@cdrjournal.com

    Journal Data Analysis

    Total publications: 179

Membership
    • COPE

      Cancer Drug Resistance is a member of the Committee on Publication Ethics (COPE) and fully adhere to its Code of Conduct and to its Best Practice Guidelines.

    • STM

      Cancer Drug Resistance is a member of and subscribes to the principles of STM. Authors of cdr can reuse a certain quantity of article contents from the chargeable publications of other STM members for free in their submissions to cdr.

    • ORCID

      Cancer Drug Resistance is a member of ORCID and our MESAs system has been connected with ORCID. After submissions to cdr are published, they will be automatically synchronized to the authors' ORCID accounts if the authors have connected their MESAs accounts with ORCID accounts. cdr's reviewers can choose to synchronize their review records to their ORCID accounts when filling in review reports.

    • Crossref

      Cancer Drug Resistance is a member of Crossref, which makes research outputs easy to find, cite, link, assess, and reuse.

    • iThenticate

      All submissions to Cancer Drug Resistance are checked for plagiarism by iThenticate.

    • Check for updates

      All published articles in Cancer Drug Resistance are enriched with a record of the current article status.

Partners